Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

Regulus Therapeutics Inc. (RGLS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 4 Collier Kathryn J (Director) has filed a Form 4 on Regulus Therapeutics Inc.
Txns: Granted 15,000 options to buy @ $1.36, valued at $20.4k
08/14/2023 4 Witz Pascale (Director) has filed a Form 4 on Regulus Therapeutics Inc.
Txns: Granted 15,000 options to buy @ $1.36, valued at $20.4k
08/14/2023 4 Rosen Hugh (Director) has filed a Form 4 on Regulus Therapeutics Inc.
Txns: Granted 15,000 options to buy @ $1.36, valued at $20.4k
08/14/2023 4 RASTETTER WILLIAM H (Director) has filed a Form 4 on Regulus Therapeutics Inc.
Txns: Granted 15,000 options to buy @ $1.36, valued at $20.4k
08/14/2023 4 PAPADOPOULOS STELIOS (Director) has filed a Form 4 on Regulus Therapeutics Inc.
Txns: Granted 15,000 options to buy @ $1.36, valued at $20.4k
08/14/2023 4 Nunn Jason Raleigh (Director) has filed a Form 4 on Regulus Therapeutics Inc.
Txns: Granted 15,000 options to buy @ $1.36, valued at $20.4k
08/14/2023 4 Klassen Preston (President & Head of R & D) has filed a Form 4 on Regulus Therapeutics Inc.
Txns: Granted 225,000 options to buy @ $1.36, valued at $306k
08/14/2023 4 Huang Alice Shih-hou (Director) has filed a Form 4 on Regulus Therapeutics Inc.
Txns: Granted 15,000 options to buy @ $1.36, valued at $20.4k
08/14/2023 4 CALSADA CRISPINA (CFO) has filed a Form 4 on Regulus Therapeutics Inc.
Txns: Granted 375,000 options to buy @ $1.36, valued at $510k
08/14/2023 4 Hagan Joseph P (President and CEO) has filed a Form 4 on Regulus Therapeutics Inc.
Txns: Granted 1,312,500 options to buy @ $1.36, valued at $1.8M
08/14/2023 4 BALTIMORE DAVID (Director) has filed a Form 4 on Regulus Therapeutics Inc.
Txns: Granted 15,000 options to buy @ $1.36, valued at $20.4k
08/14/2023 4 Aker Christopher Ray (Sr. VP & General Counsel) has filed a Form 4 on Regulus Therapeutics Inc.
Txns: Granted 393,750 options to buy @ $1.36, valued at $535.5k
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates"
06/29/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/12/2023 4 Klassen Preston (President & Head of R & D) has filed a Form 4 on Regulus Therapeutics Inc.
Txns: Granted 350,000 options to buy @ $1.46, valued at $511k
06/12/2023 3 Klassen Preston (President & Head of R & D) has filed a Form 3 on Regulus Therapeutics Inc.
06/12/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/12/2023 SC 13D/A Growth Equity Opportunities V, LLC reports a 10% stake in Regulus Therapeutics Inc.
05/11/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates"
05/10/2023 SC 13G/A FEDERATED HERMES, INC. reports a 19.9% stake in REGULUS THERAPEUTICS, INC.
04/14/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/13/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Certificate of Designation of Preferences, Rights and Limitations of Class A-5 Convertible Preferred Stock",
"Securities Purchase Agreement, by and among the Company and the Purchasers",
"Regulus Therapeutics Announces $15 Million Private Placement of Equity"
03/23/2023 10-K Annual Report for the period ended December 31, 2022
03/23/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates"
02/01/2023 SC 13G/A FEDERATED HERMES, INC. reports a 17.2% stake in REGULUS THERAPEUTICS, INC.
01/31/2023 SC 13G/A VICTORY CAPITAL MANAGEMENT INC reports a 5% stake in Regulus Therapeutics Inc.
01/17/2023 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
01/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/11/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy